WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a global, multi-year ...
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced it has entered into a ...
ImmunoGen, Inc. IMGN announced that it has entered into a global, multi-target, definitive licensing agreement with pharma giant Eli Lilly and Company LLY. ImmunoGen granted Lilly exclusive rights to ...
With ImmunoGen (NASDAQ: IMGN) shares sliding by more than 39% in the past 12 months, its investors are bound to be looking for salvation. What's more, despite recent clinical trial results that ...
ImmunoGen Inc. (IMGN +0.00%), an oncology biotech company that specializes in the use of antibody-drug conjugates (ADCs) to make chemotherapy treatments more effective, saw its shares rise by 20.3% in ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceutical’s entry into the market for ovarian cancer treatments. ImmunoGen Inc. developed the ...
ImmunoGen, Inc. (NASDAQ:IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE:TAK) to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen will receive ...
ImmunoGen's specialty is developing antibody-drug conjugates (ADCs), which you can think of as especially complicated medicines that excel in delivering molecules with therapeutic effects to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results